Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Cipla
McKinsey
Deloitte
US Department of Justice
Argus Health
Queensland Health
Boehringer Ingelheim

Generated: November 16, 2018

DrugPatentWatch Database Preview

LOVENOX Drug Profile

« Back to Dashboard

When do Lovenox patents expire, and when can generic versions of Lovenox launch?

Lovenox is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX is enoxaparin sodium. There are thirteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

US Patents and Regulatory Information for LOVENOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-005 Mar 27, 1998 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-003 Mar 27, 1998 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-007 Jun 2, 2000 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-002 Jan 30, 1998 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for LOVENOX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LOVENOX
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Cipla
McKinsey
Deloitte
US Department of Justice
Argus Health
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.